log in
Print | Back

Lowenstein Sandler LLP

Profile

Steve provides legal and strategic business counsel based upon his decades of experience at top-tier law firms and in-house as general counsel of public and private companies in diverse and highly regulated industries. His clients especially value his ability to balance a business-oriented approach to problem-solving with an appreciation for legal complexity and risk.

Steve has served in a variety of senior corporate functions, including as Chief Legal Officer and member of the Executive Committee at a multi-national public company engaged in the development, manufacturing, and distribution of pharmaceuticals and chemicals with offices and operations in 10 countries. He advised senior management and the board on all legal and regulatory matters, including, mergers and acquisitions, litigation, corporate governance, securities, antitrust, intellectual property, and human resources. Steve’s noteworthy matters include a successful litigation challenging the Department of Veterans Affairs’ interpretation of the Trade Agreements Act of 1979 and the Federal Acquisition Regulation regarding the procurement of products of certain foreign countries, resulting in a U.S. Court of Federal Claims ruling (the substance of which was affirmed by the U.S. Court of Appeals for the Federal Circuit) which not only benefited his client but which had important commercial significance for the pharmaceutical industry and for industry generally.

For more than 10 years, Steve was General Counsel to an SEC-registered investment adviser, overseeing all legal, compliance, and regulatory matters. He served as lead strategic advisor to numerous portfolio companies, advising on legal matters impacting core investment themes, including consumer goods, pharmaceuticals, health care, chemicals, mergers and acquisitions, financial services/credit facilities, and transportation.

Steve works closely with the firm’s Securities Litigation group, focusing on class action opt-out litigation, investor appraisal rights, and bondholders’ rights. The group has recovered hundreds of millions of dollars for professional investors.

Steve began his legal career in private practice at an Am Law 200 firm, focusing on both corporate and securities litigation matters.

Bar Admissions

    New York
    Connecticut
    U.S. District Court for the Southern District of New York
    U.S. District Court for the Eastern District of New York
    U.S. District Court for the Northern District of New York
    U.S. District Court for the District of Connecticut
    U.S. Court of Appeals for the Second Circuit
    U.S. Supreme Court

Education

Fordham University School of Law (J.D. 1986)
State University of New York at Binghamton (B.A. 1983)
Areas of Practice

Bankruptcy, Financial Reorganization & Creditors' Rights | Business Litigation | Capital Markets & Securities | Corporate | Corporate Governance & Compliance | Investment Management | Mergers & Acquisitions | Securities Litigation | Transactions & Advisory Group

Professional Career

Significant Accomplishments

Speaking Engagements

Steven S. Rogers will be speaking on a panel at the joint NJTMA/SFNet event, “New Jersey Pharma: A Dose of Reality.” 

In the pharmaceutical industry, success often comes down to licensing details, compliance and risk management, and properly capitalizing a business to withstand periods of volatility. This panel of distinguished speakers will address some of the industry’s practical realities within this constantly changing landscape.

Moderator:

  • John Pennett, Partner-in-Charge of the Life Sciences Group and Technology Group, EisnerAmper

Speakers:

  • Steven S. Rogers, Partner at Lowenstein Sandler LLP
  • Mike Coiley, Managing Director, CIT Healthcare
  • Eve Costopoulos, Of Counsel, Loeb & Loeb LLP 
  • Dipesh Patel, General Counsel and Secretary at Rising Pharma Holdings, Inc.

Program location: EisnerAmper Offices, 111 S. Wood Avenue, Iselin, NJ



Professional Associations

Board of Directors, JCC Association of North AmericaBoard of Directors, American Associates of Ben Gurion UniversityGubernatorial Appointment, New Jersey-Israel Commission

Articles

CARES Act: Direct Grants to Institutions of Higher Education Under the Emergency Relief Fund
Lowenstein Sandler LLP, April 2020

While much of the CARES Act media focus is on the Small Business Administration’s Paycheck Protection Program and the distribution of stimulus payments, the act also provides for tens of billions of dollars in other relief. For example, the CARES Act establishes a $30...

Additional Articles

When I transitioned from a law firm to an in-house counsel position more than a quarter-century ago, many of my colleagues didn’t yet have word processors–and it was commonplace to find open general counsel jobs posted in print newspapers.

Just as they have for the world at large, rapid technological changes since the mid-1990s have forever altered in-house legal departmentsand indeed our entire industry. We’re no longer reliant on manual processes and documentation, contract management, discovery and case management are increasingly automated and tasks like preparing and overseeing submission of SEC filings and quarterly reports are now streamlined.

But new technology is just one important shift for legal departments. Indeed, the very nature of top in-house counsel’s day-to-day tasks have changed and will likely continue to evolve in the years ahead.

In a proposal originally penned by the Treasury Department and taken up by Senate Republicans, the Trump Administration seeks passage of a nearly $1 trillion Novel Coronavirus/COVID-19 relief and economic stimulus plan that would include specific industry bailouts and payments to individuals. The White House proposal includes:

  • $500 billion for payments to individual Americans, in two equal installments;
  • $50 billion to bailout the airline industry;
  • $150 billion for relief of “other severely distressed sectors of the US economy...”; and
  • $300 billion for small business interruption loans.

Senate Democrats have outlined a competing $750 billion economic stimulus package that includes $400 billion to fund a wide array of programs (e.g., medical supplies and treatment capacity; education and child care; and expanded access to home care for senior citizens) and $350 billion of direct support to individual Americans (increased unemployment benefits; relief for student loans; and forbearance on all federally backed mortgages).

Faced with a pandemic, we expect that the negotiations to finalize and pass an economic stimulus bill will be a bipartisan effort not witnessed on Capitol Hill since President Trump took office. Despite Senators McConnell and Schumer having a long history of animosity towards each other, the circumstances presented by Novel Coronavirus/COVID-19 will likely result in fast passage of a negotiated plan that combines parts of both the White House and Democratic proposals.

The White House’s economic stimulus package proposal was preceded earlier this week by a request to Congress for approval of $45.8 billion in supplemental spending for various federal agencies involved with the government response to the pandemic, including the Veterans Health Administration ($16.6 billion), the Department of Health and Human Services ($11.5 billion), the Defense Department ($8.3 billion), and the Department of Homeland Security ($3.2 billion).

Lowenstein Sandler is committed to helping our clients, colleagues and communities during these unprecedented times. Our paramount concern is everyone’s health and safety, and doing our part to maintain the continuity of our global economy is integral to that objective. As soon as details of the economic stimulus plan becomes evident, we will provide in-depth alerts on specific aspects of the new law.

To see our other material related to the pandemic, please visit the Coronavirus/COVID-19: Facts, Insights & Resources page of our website by clicking here.


WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2020